Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Analysis Identifies Potential Biomarker of Frailty in Multiple Myeloma

January 3rd 2022, 6:00pm


Neutrophil to lymphocyte ratio may indicate the presence of frailty among older adults with multiple myeloma.

Dr Robert Rifkin Discusses Treatment Resistance in Multiple Myeloma

December 31st 2021, 2:00pm


Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, outlines the importance of studying treatment resistant patients with multiple myeloma.

Upcoming Post-Conference Perspectives: ASH 2021

December 23rd 2021, 2:00pm


Rafael Fonseca, MD, shares his excitement for an upcoming AJMC Post-Conferences Perspectives video series covering the 2021 American Society of Hematology annual meeting.

Phase 1/2 Trial Results Underscore Teclistamab’s Efficacy in RRMM

December 22nd 2021, 1:15pm


Updated results of the MajesTEC -1 phase 1/2 study on teclistamab showed the treatment resulted in an overall response rate of 62% among heavily pretreated patients with multiple myeloma.

Dr Robert Rifkin Explains the Importance of Real-world Data in MM Patient Populations

December 20th 2021, 1:00pm


Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, describes his research on real-world treatment patterns among patients with triple-class refractory multiple myeloma.

iStopMM: Investigators From Iceland Report First Results of Population-Based Screening for Multiple Myeloma

December 18th 2021, 4:57pm


Five years ago, investigators in Iceland sought to evaluate what would happen if screening for MGUS were widely available—and whether it would improve overall survival.

Sub-Q Isatuximab Combo Offers Safety, Efficacy Profile Comparable With Phase 3 Results in IV Formulation

December 15th 2021, 9:14pm


Subcutaneous (sub-Q) administration of isatuximab plus pomalidomide may provide survival advantages for patients with relapsed and refractory multiple myeloma, making it another treatment option for this patient group.

The MMRF: Understanding and Sharing the Genomic Landscape of Multiple Myeloma

December 8th 2021, 7:50pm


The Effect of Evolving Treatment Options on the Management of Multiple Myeloma

December 8th 2021, 3:08pm


Postmarketing Surveillance Study Finds Ixazomib Safety Profile Acceptable in RRMM

December 6th 2021, 10:30pm


Real-world evidence from Japan found ixazomib has an acceptable safety profile in patients with relapsed/refractory multiple myeloma (RRMS).